Valuation: Simcere Pharmaceutical Group Limited

Market Cap 4.04B 31.72B 3.5B 3.28B 2.99B 5.63B 386B 5.73B 38.45B 15.07B 193B 15.18B 14.85B 644B P/E 2026 *
16x
P/E 2027 * 13.9x
Enterprise Value 3.86B 30.25B 3.34B 3.13B 2.85B 5.37B 368B 5.46B 36.67B 14.37B 184B 14.48B 14.16B 614B EV / Sales 2026 *
2.58x
EV / Sales 2027 * 2.32x
Free-Float
32.48%
Yield 2026 *
3.33%
Yield 2027 * 3.84%
30/07 Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026 CI
09/07 Simcere Pharma's Acute Ischemic Stroke Included in National Essential Medicines List MT
15/06 Simcere Pharma Gets China Nod for Tumor Drug Trial MT
12/06 Simcere Pharmaceutical Group Limited Receives Clinical Trial Approval for Sim0689 Pd-1/Vegf Bispecific Antibody CI
12/06 Simcere Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2025, Payable on or Before July 13, 2026 CI
12/06 Simcere Pharmaceutical Group Limited Enters into A Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis CI
02/06 Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug MT
01/06 Simcere Pharmaceutical Group Limited Enters into Exclusive Promotion Service Agreement with PrimeGenX Therapeutics Co., Ltd CI
21/05 Simcere Pharmaceutical Group Limited Proposes to Declare A Final Dividend for the Year Ended December 31, 2025 CI
06/05 Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0613 LRRC15 Antibody Drug Conjugate CI
06/05 Simcere pharmaceutical receives NMPA China clinical trial approval for SIM0613 RE
06/05 Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug MT
04/05 Wuxi Biocity Biopharmaceutics Co., Ltd. announced that it has received funding from Simcere Pharmaceutical Group Limited, First Light Capital CI
1 day-1.62%
1 week+0.33%
Current month-1.62%
1 month-2.49%
3 months+4.83%
6 months-1.06%
Current year+1.50%
1 week 11.63
Extreme 11.63
12.8
1 month 11.63
Extreme 11.63
13.52
Current year 9.07
Extreme 9.07
14.28
1 year 9.07
Extreme 9.07
15.08
3 years 4.94
Extreme 4.94
15.08
5 years 4.94
Extreme 4.94
15.08
10 years 4.94
Extreme 4.94
15.08
Manager TitleAgeSince
Chief Executive Officer 54 25/03/2026
Director of Finance/CFO 55 19/11/2019
Chief Tech/Sci/R&D Officer 51 01/12/2023
Director TitleAgeSince
Chairman 63 08/10/2012
Director/Board Member 55 19/11/2019
Director/Board Member 46 01/11/2019
Date Insider Type Main position Quantity % Market Cap.
13/7/26 Other

Founder

-47,000 0.0018%
13/7/26 Other

Director

-47,000 0.0018%
10/7/26 Other

Founder

-53,000 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%+0.33%-0.08%+89.55% 4.04B
-0.63%-0.57%+18.91%+70.06% 48.85B
-2.47%+3.77%+55.63%+121.20% 41.43B
+0.53%+6.90%+25.41%+86.78% 12.46B
+0.02%+0.40%-3.74%+18.54% 12.39B
+1.25%-0.38%+30.98%+136.36% 9.08B
-1.61%+7.35%+24.40%+39.78% 7.53B
-0.12%+5.00%+40.26%-12.95% 7.14B
+0.99%+1.79%+11.72%+188.27% 6.73B
-1.22%+4.46%-25.04%+29.64% 5.88B
Average -0.32%+3,389.19%+17.85%+76.72% 15.55B
Weighted average by Cap. -0.79%+4,891.20%+26.89%+83.61%

Financials

2026 *2027 *
Net sales 1.49B 11.73B 1.3B 1.21B 1.11B 2.08B 143B 2.12B 14.22B 5.57B 71.35B 5.61B 5.49B 238B 1.69B 13.25B 1.46B 1.37B 1.25B 2.35B 161B 2.39B 16.06B 6.29B 80.6B 6.34B 6.2B 269B
Net income 246M 1.93B 213M 200M 182M 343M 23.47B 349M 2.34B 917M 11.75B 924M 904M 39.19B 292M 2.29B 253M 237M 216M 407M 27.89B 414M 2.78B 1.09B 13.96B 1.1B 1.07B 46.57B
Net Debt -187M -1.47B -162M -152M -138M -260M -17.82B -265M -1.78B -697M -8.92B -702M -686M -29.76B -123M -962M -106M -99.44M -90.74M -171M -11.69B -174M -1.17B -457M -5.85B -460M -450M -19.52B
Logo Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
7,038
Date Price Change Volume
12/08/26 HKD 12.22 -1.05% 4,068,040
11/08/26 HKD 12.35 0.00% 7,020,200
10/08/26 HKD 12.35 -0.80% 5,447,000
07/08/26 HKD 12.45 +1.55% 7,569,812
06/08/26 HKD 12.26 +1.24% 5,159,800
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.62CNY
Average target price
15.33CNY
Spread / Average Target
+44.34%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2096 Stock